At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

Digital tools, powered by intuitive design, AI, and customer centricity, offer a unique opportunity to bridge the trust gap ...

Artificial intelligence startup Quibim has raised $50 million in first-round financing to support the rollout of its ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Over 6.3 million patients make up the NHS backlog for consultant-led elective care, which reached 7,573,212 in September 2024 ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies originally ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...